The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer
The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint is to evaluate overall survival.
Metastatic Colon Cancer|Surgery
PROCEDURE: resection of primary tumor|DRUG: XELOX|DRUG: mFOLFOX6
Overall survival, 5-year
Progression-free survival 1, The first progression time after diagnosis, 3-year|Progression-free survival 2, The first progression time after randomization, 3-year|The rate of adverse events resulted from chemotherapy, The ratio of the number of patients experienced adverse events to the total patients, 3-year|The quality of life postoperatively, The European Organization for Research and Treatment (EORTC)-QLQ-C30 HRQL questionnaire was assessed with repeated measures at regular intervals postoperatively at months 3, 6, 9, 12, 18, and 24, 3-month, 6-month, 9-month, 12-month, 18-month, 24-month|Objective response rate, 1-year|The rate of postoperative complications, The ratio of the number of patients with postoperative complications to the total patients, 1-year|The proportion of surgical intervention in control group, 1-year
The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint is to evaluate overall survival.